Amarin Corp Plc (AMRN)

[ziploc_1]

Prior to the judge DU decision Amarin was anticipating a huge demand for API and making contracts, which were sufficient to fulfill that demand...Post the judge DU decision, infringing generic companies immediately came on strong....This caused a marked reduction in expected Vascepa revenues, thus forcing Amarin to fire reps and to essentially cease advertisements of Vascepa...The market that Amarin had previously anticipated for Vascepa and that had stimulated Amarin to seek large amounts of API, had evaporated due to the generics infringing on the CVD indication and the consequent loss of revenues for Amarin.